626 Pharmacokinetics and pharmacodynamics of valopicitabine (NM283), a new nucleoside HCV polymerase inhibitor: Results from a phase I/II dose-escalation trial in patients with HCV-1 infection
- 30 April 2005
- journal article
- abstracts
- Published by Elsevier in Journal of Hepatology
- Vol. 42, 229
- https://doi.org/10.1016/s0168-8278(05)82037-9
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: